LetterLetter
Successful Management of Checkpoint Inhibitor-Induced Arthritis With Disease-Modifying Antirheumatic Drugs During Active Immune Checkpoint Inhibition Treatment
Helga B. Brynjarsdottir, Sara Bjursten, Max Levin, Inger Gjertsson and Anna Rudin
The Journal of Rheumatology April 2023, jrheum.221182; DOI: https://doi.org/10.3899/jrheum.221182
Helga B. Brynjarsdottir
Helga B. Brynjarsdottir, MD, Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy at University of Gothenburg; Department of Rheumatology, Sahlgrenska University Hospital.
Sara Bjursten
Sara Bjursten, MD, Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg; Department of Oncology, Sahlgrenska University Hospital.
Max Levin
Max Levin, MD, PhD, Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg; Department of Oncology, Sahlgrenska University Hospital; Department of Molecular and Clinical Medicine/Wallenberg Laboratory, Institute of Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
Inger Gjertsson
Inger Gjertsson,MD, PhD, Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy at University of Gothenburg; Department of Rheumatology, Sahlgrenska University Hospital.
Anna Rudin
Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy at University of Gothenburg; Department of Rheumatology, Sahlgrenska University Hospital.
Abstract
Arthritis induced by immune checkpoint inhibitors (ICPi) has been reported to occur in 1% to 7% of ICPi-treated patients with cancer.1-4 Treatment generally starts with glucocorticoids (GCs) before disease-modifying antirheumatic drugs (DMARDs) are considered.5
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Successful Management of Checkpoint Inhibitor-Induced Arthritis With Disease-Modifying Antirheumatic Drugs During Active Immune Checkpoint Inhibition Treatment
Helga B. Brynjarsdottir, Sara Bjursten, Max Levin, Inger Gjertsson, Anna Rudin
The Journal of Rheumatology Apr 2023, jrheum.221182; DOI: 10.3899/jrheum.221182
Successful Management of Checkpoint Inhibitor-Induced Arthritis With Disease-Modifying Antirheumatic Drugs During Active Immune Checkpoint Inhibition Treatment
Helga B. Brynjarsdottir, Sara Bjursten, Max Levin, Inger Gjertsson, Anna Rudin
The Journal of Rheumatology Apr 2023, jrheum.221182; DOI: 10.3899/jrheum.221182